ICON plc

iconplc.com

ICON is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. We specialise in the strategic development, management and analysis of programmes that support Clinical Development - from compound selection to Phase I-IV clinical studies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

ASTRAZENECA'S CALQUENCE FAILS COVID-19 STUDY, JOINING THE LIST OF REPURPOSED MEDS THAT HAVE FALLEN SHORT

AstraZeneca | November 13, 2020

news image

Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in two tests in hospitalized patients. AstraZeneca said Thursday that the medicine—already approved in mantle cell lymphoma—didn't help patients survive the virus and reduce respiratory failure any better th...

Read More

PHARMA TECH

SPECIFICA ANNOUNCES ANTIBODY DISCOVERY PLATFORM TRANSFER AGREEMENT WITH SANOFI

Specifica | June 03, 2022

news image

Specifica, a privately held antibody engineering company focused on innovative in vitro antibody libraries and discovery tools, announced an agreement with the global healthcare company Sanofi under which Specifica’s patented Generation 3 Antibody Discovery Platform will be transferred to Sanofi. The comprehensive technology transfer package will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs. “<...

Read More

BUSINESS INSIGHTS

TRIS PHARMA ANNOUNCES DEVELOPMENT OF A VERY LOW SODIUM AND ONCE-NIGHTLY OXYBATE FORMULATION

Tris Pharma, Inc. | July 28, 2022

news image

Tris Pharma, Inc. a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that it has successfully developed an oxybate formulation for the treatment of cataplexy or excessive daytime sleepiness n patients 7 years of age and older with narcolepsy that has the potential to be significantly advantageous to existing approved therapies, such as Jazz Pharmaceuticals' blockbuster XYWAV® and XYREM® franchise. The Tris oxybate formulation is believed to pr...

Read More

PHARMA TECH

WARBURG PINCUS ANNOUNCES ACQUISITION OF PHARMA INTELLIGENCE FROM INFORMA

Warburg Pincus | February 11, 2022

news image

Warburg Pincus, a leading global growth investor, tannounced the acquisition of Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC the international B2B markets knowledge services and business intelligence group. Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. The investors plan to extend the company's leading posi...

Read More
news image

PHARMA TECH

ASTRAZENECA'S CALQUENCE FAILS COVID-19 STUDY, JOINING THE LIST OF REPURPOSED MEDS THAT HAVE FALLEN SHORT

AstraZeneca | November 13, 2020

Months after drugmakers launched an unprecedented COVID-19 research effort, some existing medicines have turned in promising results—but more of them have failed against the virus. And AstraZeneca’s blood cancer med Calquence just became one of them, falling short in two tests in hospitalized patients. AstraZeneca said Thursday that the medicine—already approved in mantle cell lymphoma—didn't help patients survive the virus and reduce respiratory failure any better th...

Read More
news image

PHARMA TECH

SPECIFICA ANNOUNCES ANTIBODY DISCOVERY PLATFORM TRANSFER AGREEMENT WITH SANOFI

Specifica | June 03, 2022

Specifica, a privately held antibody engineering company focused on innovative in vitro antibody libraries and discovery tools, announced an agreement with the global healthcare company Sanofi under which Specifica’s patented Generation 3 Antibody Discovery Platform will be transferred to Sanofi. The comprehensive technology transfer package will enable the integration of Specifica’s Gen 3 platform into Sanofi’s antibody discovery programs. “<...

Read More
news image

BUSINESS INSIGHTS

TRIS PHARMA ANNOUNCES DEVELOPMENT OF A VERY LOW SODIUM AND ONCE-NIGHTLY OXYBATE FORMULATION

Tris Pharma, Inc. | July 28, 2022

Tris Pharma, Inc. a fully integrated pharmaceutical company with a robust portfolio of CNS products announced that it has successfully developed an oxybate formulation for the treatment of cataplexy or excessive daytime sleepiness n patients 7 years of age and older with narcolepsy that has the potential to be significantly advantageous to existing approved therapies, such as Jazz Pharmaceuticals' blockbuster XYWAV® and XYREM® franchise. The Tris oxybate formulation is believed to pr...

Read More
news image

PHARMA TECH

WARBURG PINCUS ANNOUNCES ACQUISITION OF PHARMA INTELLIGENCE FROM INFORMA

Warburg Pincus | February 11, 2022

Warburg Pincus, a leading global growth investor, tannounced the acquisition of Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC the international B2B markets knowledge services and business intelligence group. Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. The investors plan to extend the company's leading posi...

Read More